Want to see FR:DIM full AI Analyst Report?
DIM Stock Chart & Stats
€188.70
€3.85(1.94%)
At close: 4:00 PM EST
€188.70
€3.85(1.94%)
Day’s Range― - ―
52-Week Range€150.00 - €224.00
Previous CloseN/A
Volume6.35K
Average Volume (3M)78.09K
Market Cap
€17.72B
Enterprise Value€19.29B
Total Cash (Recent Filing)€521.20M
Total Debt (Recent Filing)€2.61B
Price to Earnings (P/E)66.2
Beta1.51
Next Earnings
Jul 23, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)2.75
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€225.67Price Target Upside19.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5.1
Revenue Forecast (FY)€3.17B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelSartorius's core business sells single-use assemblies, filtration consumables and related services that customers repurchase as they run production. That recurring consumables stream creates predictable, high-frequency revenue and customer stickiness, supporting durable topline visibility and long-term cash generation.
TTM Revenue Rebound & Operating MarginsA sharp ~57% TTM revenue recovery coupled with solid EBIT and EBITDA margins indicates resurgent demand and operational leverage. Sustained revenue growth with reasonable operating profitability improves scale economics and provides runway to reinvest in products, supporting medium-term earnings resilience.
Improving LeverageMaterial reduction in leverage from prior peak materially eases interest and refinancing pressure. A healthier debt-to-equity ratio increases financial flexibility for capex, R&D or M&A, lowering default risk and enabling management to execute strategic initiatives over the coming months.
Bears Say
Margin CompressionMargins have meaningfully compressed from prior peaks, signaling structural margin pressure from cost inflation, pricing or mix shifts. Lower gross and net margins reduce the firm's ability to convert revenue into durable profits, constraining long-term return potential absent a margin recovery.
Weak FCF ConversionFree-cash-flow is a modest portion of operating earnings, indicating working-capital drag or higher reinvestment needs. Persistently weak FCF conversion limits capacity to deleverage, fund growth internally, or increase shareholder returns without external financing, weakening financial resilience.
Sizeable Debt & Modest ROEAlthough leverage has improved, absolute debt remains material and ROE is muted. Elevated debt levels increase fixed costs and reduce strategic optionality, while modest ROE implies limited efficiency in converting equity into returns, pressuring shareholder value if growth stalls.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €150.00 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €17.72B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Jul 23, 2026 which is in 19 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Apr 23, 2026. The company reported €1.17 earnings per share for the quarter, missing the consensus estimate of €1.211 by -€0.041.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Notavailable dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.26.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.17 in its last earnings report, missing expectations of €1.211. Following the earnings report the stock price went down -14.185%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
DIM Stock 12 Month Forecast
Average Price Target
€225.67
▲(19.59% Upside)
Technical Analysis
Options Prices
Currently, No data available
---